Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2007

Open Access 01-12-2007 | Research article

Favorable prognostic value of SOCS2 and IGF-I in breast cancer

Authors: Michael C Haffner, Barbara Petridou, Jean Phillipe Peyrat, Françoise Révillion, Elisabeth Müller-Holzner, Günter Daxenbichler, Christian Marth, Wolfgang Doppler

Published in: BMC Cancer | Issue 1/2007

Login to get access

Abstract

Background

Suppressor of cytokine signaling (SOCS) proteins comprise a protein family, which has initially been described as STAT induced inhibitors of the Jak/Stat pathway. Recent in vivo and in vitro studies suggest that SOCS proteins are also implicated in cancer. The STAT5 induced IGF-I acts as an endocrine and para/autocrine growth and differentiation factor in mammary gland development. Whereas high levels of circulating IGF-I have been associated with increased cancer risk, the role of autocrine acting IGF-I is less clear. The present study is aimed to elucidate the clinicopathological features associated with SOCS1, SOCS2, SOCS3, CIS and IGF-I expression in breast cancer.

Methods

We determined the mRNA expression levels of SOCS1, SOCS2, SOCS3, CIS and IGF-I in 89 primary breast cancers by reverse transcriptase PCR. SOCS2 protein expression was further evaluated by immuno-blot and immunohistochemistry.

Results

SOCS2 expression inversely correlated with histopathological grade and ER positive tumors exhibited higher SOCS2 levels. Patients with high SOCS2 expression lived significantly longer (108.7 vs. 77.7 months; P = 0.015) and high SOCS2 expression proved to be an independent predictor for good prognosis (HR = 0.45, 95% CI 0.23 – 0.91, P = 0.026). In analogy to SOCS2, high IGF-I expression was an independent predictor for good prognosis in the entire patient cohort. In the subgroup of patients with lymph-node negative disease, high IGF-I was a strong predictor for favorable outcome in terms of overall survival and relapse free survival (HR = 0.075, 95% CI 0.014 – 0.388, P = 0.002).

Conclusion

This is the first report on the favorable prognostic value of high SOCS2 expression in primary mammary carcinomas. Furthermore a strong association of high IGF-I expression levels with good prognosis was observed especially in lymph-node negative patients. Our results suggest that high expression of the STAT5 target genes SOCS2 and IGF-I is a feature of differentiated and less malignant tumors.
Appendix
Available only for authorised users
Literature
1.
Alexander WS, Hilton DJ: The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol. 2004, 22: 503-529. 10.1146/annurev.immunol.22.091003.090312.CrossRefPubMed
2.
Ryo A, Suizu F, Yoshida Y, Perrem K, Liou YC, Wulf G, Rottapel R, Yamaoka S, Lu KP: Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell. 2003, 12 (6): 1413-1426. 10.1016/S1097-2765(03)00490-8.CrossRefPubMed
3.
4.
De Sepulveda P, Okkenhaug K, Rose JL, Hawley RG, Dubreuil P, Rottapel R: Socs1 binds to multiple signalling proteins and suppresses steel factor-dependent proliferation. Embo J. 1999, 18 (4): 904-915. 10.1093/emboj/18.4.904.CrossRefPubMedPubMedCentral
5.
Rui L, Yuan M, Frantz D, Shoelson S, White MF: SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem. 2002, 277 (44): 42394-42398. 10.1074/jbc.C200444200.CrossRefPubMed
6.
De Sepulveda P, Ilangumaran S, Rottapel R: Suppressor of cytokine signaling-1 inhibits VAV function through protein degradation. J Biol Chem. 2000, 275 (19): 14005-14008. 10.1074/jbc.C000106200.CrossRefPubMed
7.
Oshimo Y, Kuraoka K, Nakayama H, Kitadai Y, Yoshida K, Chayama K, Yasui W: Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma. Int J Cancer. 2004, 112 (6): 1003-1009. 10.1002/ijc.20521.CrossRefPubMed
8.
Sutherland KD, Lindeman GJ, Choong DY, Wittlin S, Brentzell L, Phillips W, Campbell IG, Visvader JE: Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene. 2004, 23 (46): 7726-7733. 10.1038/sj.onc.1207787.CrossRefPubMed
9.
Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, Harris CC, Herman JG: SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet. 2001, 28 (1): 29-35. 10.1038/88225.PubMed
10.
Weber A, Hengge UR, Bardenheuer W, Tischoff I, Sommerer F, Markwarth A, Dietz A, Wittekind C, Tannapfel A: SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene. 2005, 24 (44): 6699-6708. 10.1038/sj.onc.1208818.CrossRefPubMed
11.
He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, Costello JF, McCormick F, Jablons DM: SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A. 2003, 100 (24): 14133-14138. 10.1073/pnas.2232790100.CrossRefPubMedPubMedCentral
12.
Watanabe D, Ezoe S, Fujimoto M, Kimura A, Saito Y, Nagai H, Tachibana I, Matsumura I, Tanaka T, Kanegane H, Miyawaki T, Emi M, Kanakura Y, Kawase I, Naka T, Kishimoto T: Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. Br J Haematol. 2004, 126 (5): 726-735. 10.1111/j.1365-2141.2004.05107.x.CrossRefPubMed
13.
Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG: SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood. 2003, 101 (7): 2784-2788. 10.1182/blood-2002-06-1735.CrossRefPubMed
14.
Rottapel R, Ilangumaran S, Neale C, La Rose J, Ho JM, Nguyen MH, Barber D, Dubreuil P, de Sepulveda P: The tumor suppressor activity of SOCS-1. Oncogene. 2002, 21 (28): 4351-4362. 10.1038/sj.onc.1205537.CrossRefPubMed
15.
Pollak MN, Schernhammer ES, Hankinson SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004, 4 (7): 505-518. 10.1038/nrc1387.CrossRefPubMed
16.
Wood TL, Richert MM, Stull MA, Allar MA: The insulin-like growth factors (IGFs) and IGF binding proteins in postnatal development of murine mammary glands. J Mammary Gland Biol Neoplasia. 2000, 5 (1): 31-42. 10.1023/A:1009511131541.CrossRefPubMed
17.
Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE: The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev. 2000, 21 (3): 215-244. 10.1210/er.21.3.215.CrossRefPubMed
18.
Widschwendter A, Tonko-Geymayer S, Welte T, Daxenbichler G, Marth C, Doppler W: Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin Cancer Res. 2002, 8 (10): 3065-3074.PubMed
19.
Marth C, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Doppler W, Daxenbichler G: Interferon-gamma expression is an independent prognostic factor in ovarian cancer. Am J Obstet Gynecol. 2004, 191 (5): 1598-1605. 10.1016/j.ajog.2004.05.007.CrossRefPubMed
20.
Bieche I, Onody P, Laurendeau I, Olivi M, Vidaud D, Lidereau R, Vidaud M: Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem. 1999, 45 (8 Pt 1): 1148-1156.PubMed
21.
Masuhara M, Sakamoto H, Matsumoto A, Suzuki R, Yasukawa H, Mitsui K, Wakioka T, Tanimura S, Sasaki A, Misawa H, Yokouchi M, Ohtsubo M, Yoshimura A: Cloning and characterization of novel CIS family genes. Biochem Biophys Res Commun. 1997, 239 (2): 439-446. 10.1006/bbrc.1997.7484.CrossRefPubMed
22.
Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Gastl G, Gunsilius E, Marth C: The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res. 2005, 11 (23): 8326-8331. 10.1158/1078-0432.CCR-05-1244.CrossRefPubMed
23.
Farabegoli F, Ceccarelli C, Santini D, Taffurelli M: Suppressor of cytokine signalling 2 (SOCS-2) expression in breast carcinoma. J Clin Pathol. 2005, 58 (10): 1046-1050. 10.1136/jcp.2004.024919.CrossRefPubMedPubMedCentral
24.
Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang D, Brown M, Bodner S, Grosveld G, Ihle JN: Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 1998, 93 (5): 841-850. 10.1016/S0092-8674(00)81444-0.CrossRefPubMed
25.
Shin A, Ren Z, Shu XO, Cai Q, Gao YT, Zheng W: Expression patterns of insulin-like growth factor 1 (IGF-I) and its receptor in mammary tissues and their associations with breast cancer survival. Breast Cancer Res Treat. 2006
26.
27.
Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, van Weerden WM, Bangma CH, Trapman J, Jenster G: Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res. 2006, 66 (10): 5012-5020. 10.1158/0008-5472.CAN-05-3082.CrossRefPubMed
28.
Wikman H, Kettunen E, Seppanen JK, Karjalainen A, Hollmen J, Anttila S, Knuutila S: Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene. 2002, 21 (37): 5804-5813. 10.1038/sj.onc.1205726.CrossRefPubMed
29.
Raccurt M, Tam SP, Lau P, Mertani HC, Lambert A, Garcia-Caballero T, Li H, Brown RJ, McGuckin MA, Morel G, Waters MJ: Suppressor of cytokine signalling gene expression is elevated in breast carcinoma. Br J Cancer. 2003, 89 (3): 524-532. 10.1038/sj.bjc.6601115.CrossRefPubMedPubMedCentral
30.
Metcalf D, Greenhalgh CJ, Viney E, Willson TA, Starr R, Nicola NA, Hilton DJ, Alexander WS: Gigantism in mice lacking suppressor of cytokine signalling-2. Nature. 2000, 405 (6790): 1069-1073. 10.1038/35016611.CrossRefPubMed
31.
Greenhalgh CJ, Rico-Bautista E, Lorentzon M, Thaus AL, Morgan PO, Willson TA, Zervoudakis P, Metcalf D, Street I, Nicola NA, Nash AD, Fabri LJ, Norstedt G, Ohlsson C, Flores-Morales A, Alexander WS, Hilton DJ: SOCS2 negatively regulates growth hormone action in vitro and in vivo. J Clin Invest. 2005, 115 (2): 397-406. 10.1172/JCI200522710.CrossRefPubMedPubMedCentral
32.
Hadsell DL, Murphy KL, Bonnette SG, Reece N, Laucirica R, Rosen JM: Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis. Oncogene. 2000, 19 (7): 889-898. 10.1038/sj.onc.1203386.CrossRefPubMed
33.
Wu Y, Cui K, Miyoshi K, Hennighausen L, Green JE, Setser J, LeRoith D, Yakar S: Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res. 2003, 63 (15): 4384-4388.PubMed
34.
Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998, 351 (9113): 1393-1396. 10.1016/S0140-6736(97)10384-1.CrossRefPubMed
35.
Voskuil DW, Bosma A, Vrieling A, Rookus MA, van 't Veer LJ: Insulin-like growth factor (IGF)-system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk. Breast Cancer Res Treat. 2004, 84 (3): 225-233. 10.1023/B:BREA.0000019954.59130.d3.CrossRefPubMed
36.
Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ, Lippman ME, Rosen N: Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol. 1989, 3 (3): 509-517.CrossRefPubMed
37.
van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002, 347 (25): 1999-2009. 10.1056/NEJMoa021967.CrossRefPubMed
38.
Davey HW, Xie T, McLachlan MJ, Wilkins RJ, Waxman DJ, Grattan DR: STAT5b is required for GH-induced liver IGF-I gene expression. Endocrinology. 2001, 142 (9): 3836-3841. 10.1210/en.142.9.3836.CrossRefPubMed
39.
Greenhalgh CJ, Bertolino P, Asa SL, Metcalf D, Corbin JE, Adams TE, Davey HW, Nicola NA, Hilton DJ, Alexander WS: Growth enhancement in suppressor of cytokine signaling 2 (SOCS-2)-deficient mice is dependent on signal transducer and activator of transcription 5b (STAT5b). Mol Endocrinol. 2002, 16 (6): 1394-1406. 10.1210/me.16.6.1394.CrossRefPubMed
40.
Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L: Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev. 1997, 11 (2): 179-186. 10.1101/gad.11.2.179.CrossRefPubMed
41.
Cui Y, Riedlinger G, Miyoshi K, Tang W, Li C, Deng CX, Robinson GW, Hennighausen L: Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol. 2004, 24 (18): 8037-8047. 10.1128/MCB.24.18.8037-8047.2004.CrossRefPubMedPubMedCentral
42.
Bratthauer GL, Strauss BL, Tavassoli FA: STAT 5a expression in various lesions of the breast. Virchows Arch. 2006, 448 (2): 165-171. 10.1007/s00428-005-0056-6.CrossRefPubMed
43.
Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J, Sauter G, Rui H: Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol. 2004, 22 (11): 2053-2060. 10.1200/JCO.2004.11.046.CrossRefPubMed
44.
Yamashita H, Nishio M, Ando Y, Zhang Z, Hamaguchi M, Mita K, Kobayashi S, Fujii Y, Iwase H: Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. Endocr Relat Cancer. 2006, 13 (3): 885-893. 10.1677/erc.1.01095.CrossRefPubMed
45.
Favre H, Benhamou A, Finidori J, Kelly PA, Edery M: Dual effects of suppressor of cytokine signaling (SOCS-2) on growth hormone signal transduction. FEBS Lett. 1999, 453 (1-2): 63-66. 10.1016/S0014-5793(99)00681-X.CrossRefPubMed
46.
Greenhalgh CJ, Metcalf D, Thaus AL, Corbin JE, Uren R, Morgan PO, Fabri LJ, Zhang JG, Martin HM, Willson TA, Billestrup N, Nicola NA, Baca M, Alexander WS, Hilton DJ: Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling. J Biol Chem. 2002, 277 (43): 40181-40184. 10.1074/jbc.C200450200.CrossRefPubMed
47.
Michaylira CZ, Ramocki NM, Simmons JG, Tanner CK, McNaughton KK, Woosley JT, Greenhalgh CJ, Lund PK: Haplotype insufficiency for suppressor of cytokine signaling-2 enhances intestinal growth and promotes polyp formation in growth hormone-transgenic mice. Endocrinology. 2006, 147 (4): 1632-1641. 10.1210/en.2005-1241.CrossRefPubMed
48.
Leung KC, Doyle N, Ballesteros M, Sjogren K, Watts CK, Low TH, Leong GM, Ross RJ, Ho KK: Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. Proc Natl Acad Sci U S A. 2003, 100 (3): 1016-1021. 10.1073/pnas.0337600100.CrossRefPubMedPubMedCentral
49.
Leong GM, Moverare S, Brce J, Doyle N, Sjogren K, Dahlman-Wright K, Gustafsson JA, Ho KK, Ohlsson C, Leung KC: Estrogen up-regulates hepatic expression of suppressors of cytokine signaling-2 and -3 in vivo and in vitro. Endocrinology. 2004, 145 (12): 5525-5531. 10.1210/en.2004-0061.CrossRefPubMed
Metadata
Title
Favorable prognostic value of SOCS2 and IGF-I in breast cancer
Authors
Michael C Haffner
Barbara Petridou
Jean Phillipe Peyrat
Françoise Révillion
Elisabeth Müller-Holzner
Günter Daxenbichler
Christian Marth
Wolfgang Doppler
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2007
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-7-136

Other articles of this Issue 1/2007

BMC Cancer 1/2007 Go to the issue

Research article

The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers

Research article

Aberrant overexpression of an epithelial marker, 14-3-3σ, in a subset of hematological malignancies

Research article

Metabolic profiling of human brain metastases using in vivo proton MR spectroscopy at 3T

Research article

Platelet-derived growth factor receptor-β, carrying the activating mutation D849N, accelerates the establishment of B16 melanoma

Research article

Synoptic tool for reporting of hematological and lymphoid neoplasms based on World Health Organization classification and College of American Pathologists checklist

Research article

Stromelysin-3 over-expression enhances tumourigenesis in MCF-7 and MDA-MB-231 breast cancer cell lines: involvement of the IGF-1 signalling pathway
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits